Sept 24 (Reuters) – Drug developer Atavistik Bio said on Thursday it has signed a deal with ‌Swiss drugmaker Roche potentially worth nearly $2 billion, ‌including milestone payments, to develop oral treatments for cardiovascular, kidney and ​metabolic diseases.

Here are some details:

• As part of the agreement, Atavistik will receive $70 million upfront and could get up to $1.9 billion in research, development and commercial milestone payments, ‌plus royalties on ⁠sales of approved drugs, the privately held drug developer said.

• The partnership covers multiple ⁠drug targets and will use Atavistik’s proprietary technology to find hidden pockets on disease-causing proteins, potentially allowing drugs to ​be developed ​against targets conventional methods ​have struggled to reach.

• ‌Unlike many traditional drugs that bind to a protein’s main active site, Atavistik’s approach targets other sites that regulate how the protein works, which could allow for more selective treatments with fewer unintended effects.

• Atavistik will ‌lead early discovery and research, ​while Roche will handle further ​lab and human ​testing, regulatory filings and commercialization, Atavistik said.

• ‌Atavistik will continue developing its ​own treatments for ​rare blood disorders, including for hereditary hemorrhagic telangiectasia, which causes malformed blood vessels.

• The companies did ​not disclose the ‌number of targets covered by the partnership or ​provide development timelines.

(Reporting by Kunal Das in ​Bengaluru; Editing by Pooja Desai)